Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast Cancer (ELONA)

An Open-Label, Phase 1b-2 Study of Elacestrant, in Combination With Onapristone in Patients With Estrogen Receptor-Positive, Progesterone Receptor-Positive, HER2-negative Advanced or Metastatic Breast Cancer (ELONA)

This is a multicenter, Phase 1b-2 study of elacestrant in combination with onapristone in patients with advanced/metastatic ER+/PgR+/HER2- breast cancer.

Study Overview

• Status: Terminated
• Conditions: Breast Cancer
• Intervention / Treatment: Drug: Elacestrant; Drug: Onapristone

Detailed Description

This is a multicenter, phase 1b-2 trial. The phase 1b part of the trial is open label and aims to determine the recommended Phase 2 dose (RP2D) of onapristone and elacestrant when administered together. The Phase 2 part of the trial will evaluate the efficacy and safety of this combination in patients with ER+/PgR+/HER2- advanced/metastatic breast cancer after prior therapy with a CDK4/6 inhibitor.

• Study Type: Interventional
• Enrollment (Actual): 4
• Phase: Phase 2; Phase 1

Contacts and Locations

Study Locations

• United States
  • Arizona
    • Phoenix, Arizona, United States, 85338
      • Cancer Treatment Centers of America - Western Regional Medical Center
  • Illinois
    • Zion, Illinois, United States, 60099
      • Cancer Treatment Centers of America - Midwestern Regional Center
  • Tennessee
    • Nashville, Tennessee, United States, 37203
      • Sarah Cannon Research Institute

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Women or men aged ≥18 years, at the time of informed consent signature. Note: Pre- and peri-menopausal women must receive goserelin for at least one month prior to initiating trial therapy, during the trial, and for at least one month after end of trial therapy. Men must receive triptorelin for at least one month prior to initiating trial therapy, during the trial and for at least one month after end of trial therapy.
2. Histopathologically or cytologically confirmed ER+, PgR+, HER2-, breast cancer, per local laboratory, as per the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines (Allison et al, 2020). Note: In the context of this trial, ER and PgR status will be considered positive if ≥10% of tumor cells demonstrate positive nuclear staining by immunohistochemistry.
3. At least one measurable lesion as per RECIST version 1.1. Note: Patients with stable brain or subdural metastases are allowed if the patient has completed local therapy and has discontinued the use of corticosteroids for at least 4 weeks before starting treatment in this study. Any signs (e.g., radiologic) or symptoms of brain metastases must be stable for at least 4 weeks before starting study treatment.
4. Prior therapy with an aromatase inhibitor or fulvestrant + a CDK4/6 inhibitor in the metastatic setting or in the adjuvant setting if within 12 months of last dose of adjuvant therapy. Note: Prior therapy with everolimus is allowed.
5. ECOG performance status of 0 or 1.

6. Patient has adequate bone marrow and organ function, as defined by the following laboratory values:

   1. Absolute neutrophil count (ANC) ≥1.5 × 109/L,
   2. Platelets ≥100 × 109/L,
   3. Hemoglobin ≥9.0 g/dL,
   4. Potassium, sodium, calcium (corrected for serum albumin), and magnesium CTCAE grade ≤1,
   5. Cockcroft-Gault-based creatinine clearance ≥50 mL/min. Note: Creatinine clearance (male) = ([140-age in years] × weight in kg)/ ([serum creatinine in mg/dL] × 72) Creatinine clearance (female) = (0.85 × [140-age in years] × weight in kg)/ ([serum creatinine in mg/dL] × 72),
   6. Serum albumin ≥3.0 g/dL (≥30 g/L),
   7. In absence of liver metastases, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3.0 × ULN. If the patient has liver metastases, ALT and AST ≤5 × ULN,
   8. Total serum bilirubin <1.5 × ULN except for patients with Gilbert's syndrome who may be included if the total serum bilirubin is ≤3.0 × ULN or direct bilirubin ≤1.5 × ULN.

Exclusion Criteria:

1. Active or newly diagnosed CNS metastases, including meningeal carcinomatosis.
2. Breast cancer treatment-naïve patients in the metastatic setting.
3. Prior therapy with elacestrant, onapristone, or chemotherapy in the metastatic setting.
4. Patient has a concurrent malignancy or history of invasive malignancy within 3 years of enrollment, with the exception of basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix that has completed curative therapy.

5. Uncontrolled significant active infections.

   1. Patients with hepatitis B virus (HBV) and/or hepatitis C virus (HCV) infection must have undetectable viral load during screening.
   2. Patients known to be HIV+ are allowed as long as they have undetectable viral load at baseline.
6. Major surgery within 4 weeks before starting trial therapy.
7. Inability to take oral medication, or history of malabsorption syndrome or any other uncontrolled gastrointestinal condition.

8. Females of childbearing potential who:

   1. Within 28 days before study entry, did not use a highly effective method of contraception.
   2. Do not agree to use a highly effective method of contraception throughout the entire study period and for 28 days after trial therapy discontinuation.
9. Males who do not agree to abstain from donating sperm, or to use a highly effective method of contraception, during the course of the treatment period and for 28 days thereafter.
10. Known intolerance to either study drug or any of the excipients.

11. Patient is currently receiving or received any of the following medications prior to first dose of trial therapy:

    1. Known strong or moderate inducers or inhibitors of cytochrome P450 (CYP) 3A4 within 14 days or 5 half-lives, whichever is shorter, (Refer to http://medicine.iupui.edu/clinpharm/ddis/),
    2. Herbal preparations/medications within 7 days. These include, but are not limited to, St. John's wort, kava, ephedra (ma huang), gingko biloba, dehydroepiandrosterone (DHEA), yohimbe, saw palmetto, and ginseng.
    3. Investigational anti-cancer therapy with 21 days or 5 half-lives, whichever is shorter.
    4. Vaccination, including but not limited to vaccination against COVID-19, during the 7 days prior to randomization.
12. Evidence of ongoing alcohol or drug abuse.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Elacestrant / Onapristone; Elacestrant and Onapristone combination	Drug: Elacestrant; Elacestrant 200mg, 300mg, or 400mg once daily oral dosing in cycles of 28 days.; Other Names: RAD1901; Drug: Onapristone; Onapristone 40mg or 50mg twice daily oral dosing in cycles of 28 days.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Determine the recommended Phase 2 dose (RP2D) of the combination of onapristone and elacestrant (Phase 1).		9 months
Evaluate the efficacy of elacestrant in combination with onapristone in terms of objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1 (Phase 2).	Proportion of patients achieving a best overall response of confirmed partial or complete response (PR+CR).	1.5 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Characterize the AEs of elacestrant in combination with onapristone.	Characterize the AEs of elacestrant in combination with onapristone.	21 months
Characterize the serious adverse events (SAEs) of elacestrant in combination with onapristone.	Characterize the serious adverse events (SAEs) of elacestrant in combination with onapristone.	21 months
Characterize the safety in terms of changes in clinical laboratory values of elacestrant in combination with onapristone.	Characterize the safety in terms of changes in clinical laboratory values of elacestrant in combination with onapristone.	21 months
Characterize the safety in terms of changes in vital sign measurements of elacestrant in combination with onapristone.	Characterize the safety in terms of changes in vital sign measurements of elacestrant in combination with onapristone.	21 months
Characterize the safety in terms of changes in ECG parameters of elacestrant in combination with onapristone.	Characterize the safety in terms of changes in ECG parameters of elacestrant in combination with onapristone.	21 months
Evaluate the area under the plasma concentration-time curve over the dosing interval of elacestrant as well as onapristone and their metabolites (Phase 1).	Evaluate the area under the plasma concentration-time curve over the dosing interval of elacestrant as well as onapristone and their metabolites (Phase 1).	9 months
Evaluate the maximum plasma concentration (Cmax) of elacestrant as well as onapristone and their metabolites (Phase 1).	Evaluate the maximum plasma concentration (Cmax) of elacestrant as well as onapristone and their metabolites (Phase 1).	9 months
Evaluate the time of the maximum observed plasma concentration (Tmax) of elacestrant as well as onapristone and their metabolites (Phase 1).	Evaluate the time of the maximum observed plasma concentration (Tmax) of elacestrant as well as onapristone and their metabolites (Phase 1).	9 months
Evaluate the trough concentration of elacestrant as well as onapristone and their metabolites (Phase 1).	Evaluate the trough concentration of elacestrant as well as onapristone and their metabolites (Phase 1).	9 months
Evaluate duration of response.	Time from the date of the first documented CR/PR until first documentation of disease progression or death, whichever comes first.	3 years
Evaluate clinical benefit rate.	Proportion of subjects achieving a best overall or complete response, or durable stable disease (duration is at least 23 weeks).	3 years
Evaluate progression-free survival.	Time from the date of the first dose to the date of the first documentation of disease progression or death, whichever occurs first.	3 years
Evaluate overall survival.	Time from first dose date to the date of death from any cause.	3 years

Collaborators and Investigators

• Sponsor: Context Therapeutics Inc.

Study record dates

Study Major Dates

• Study Start (Actual): December 2, 2022
• Primary Completion (Actual): June 23, 2023
• Study Completion (Actual): June 23, 2023

Study Registration Dates

• First Submitted: November 3, 2022
• First Submitted That Met QC Criteria: November 9, 2022
• First Posted (Actual): November 16, 2022

Study Record Updates

• Last Update Posted (Actual): May 9, 2025
• Last Update Submitted That Met QC Criteria: May 6, 2025
• Last Verified: June 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms by Site; Neoplasms; Skin Diseases; Breast Diseases; Breast Neoplasms; Antineoplastic Agents; Physiological Effects of Drugs; Hormones, Hormone Substitutes, and Hormone Antagonists; Reproductive Control Agents; Hormone Antagonists; Fertility Agents, Female; Fertility Agents; Onapristone
• Other Study ID Numbers: ONA-XR-103

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No